Charlotte Videbaek

Directeur/Membre du Conseil chez CESSATECH A/S

62 ans

Health Technology

Commercial Services

Consumer Services

Relations actives

Nom	Sexe	Age	Sociétés liées	Collaboration
Adam Sinding Steensberg	M	50	CESSATECH A/S	4 ans
Martin Olin	M	55	CESSATECH A/S	4 ans
Flemming Steen Jensen	M	63	CESSATECH A/S	4 ans
Peter Birk	M	59	CESSATECH A/S	4 ans
Jes Trygved	M	51	H. LUNDBECK A/S CESSATECH A/S	8 ans
Rachel Curtis Gravesen	F	55	CESSATECH A/S	2 ans
Louise Bak	F	-	CESSATECH A/S	3 ans

Graphique Relationnel

Relation dans plusieurs entreprises

Anciennes relations

Nom	Sexe	Age	Sociétés liées	Collaboration
Jakob W. Gotfredsen	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 ans
Ulla Hald Buhl	F	60	CESSATECH A/S	1 ans
Uno Jakob Weber	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 ans
Benedikte Bandak	F	-	CESSATECH A/S	-
Jens Peter Balling	M	-	H. LUNDBECK A/S	-
Lars Kober	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 ans
Christian Torp-Pedersen	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 ans
Anders Götzsche	M	56	H. LUNDBECK A/S	15 ans
Carsten Schou	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Kristian Sibilitz	M	-	H. LUNDBECK A/S	-
Etienne Adriansen	M	60	CESSATECH A/S	-
Steen Henneberg	M	75	CESSATECH A/S	3 ans
Bettina Nygaard Nielsen	M	47	CESSATECH A/S	-
Tugba Ceylan	F	-	H. LUNDBECK A/S	1 ans
Christoffer Erik Lorenzen	M	48	H. LUNDBECK A/S	5 ans
Iman Barilero	M	-	H. LUNDBECK A/S	-
Peter Bisgaard	M	50	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Marie-Laure Jeanne Antoinette Pochon	F	65	H. LUNDBECK A/S	5 ans
Jørgen Okkels Nielsen	M	76	H. LUNDBECK A/S	5 ans
Inge Holm Lauritzen	F	57	H. LUNDBECK A/S	9 ans
Frank Knudsen	M	66	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Klaus Bæk Simonsen	M	-	H. LUNDBECK A/S	-
Peter Moldt	M	65	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Finn Eggert Sørensen	M	70	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Helle Størum	F	57	H. LUNDBECK A/S	9 ans
Hans Henrik Munch-Jensen	M	64	H. LUNDBECK A/S	8 ans
Flemming Bent Lindeløv	M	75	H. LUNDBECK A/S	-
Egil Bodd	M	69	H. LUNDBECK A/S	-
Mads Buhl Axelsen	M	66	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Per Wold-Olsen	M	76	H. LUNDBECK A/S	4 ans

Statistiques

Pays	Relations	% du total
Danemark	37	100,00%

Age des relations

Actives

Passées

Homme

Femme

Administrateurs

Exécutifs

Provenance des relations